Last reviewed · How we verify
Sivextro 200 milligrams Oral Tablet
Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome.
Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).
At a glance
| Generic name | Sivextro 200 milligrams Oral Tablet |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Oxazolidinone antibiotic |
| Target | Bacterial 70S ribosome (peptidyl transferase center) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 70S ribosome and inhibits peptidyl transferase, preventing peptide bond formation and halting protein synthesis. This bacteriostatic mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
- Community-acquired bacterial pneumonia (CABP)
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
- Peripheral neuropathy
- Optic neuropathy
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: